The treatment of brain metastases from malignant melanoma

Seminars in Oncology

Volumn 29, Issue 5, 2002, Pages 518-524

  Douglas, James G ^a,b   Margolin, Kim ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; DACARBAZINE; FOTEMUSTINE; TEMOZOLOMIDE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG PENETRATION; HUMAN; MELANOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOBIOLOGY; RADIOSURGERY; STEREOTAXIC SURGERY;

EID: 0037010054     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.35247     Document Type: Article

References (66)

1. American Cancer Society: Cancer Facts and Figures - 1999. Atlanta, GA, ACS, 1999
2. Amer MH, Al-Sarraf M, Baker LH, et al: Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 42:660-668, 1978
3. Chason J, Walker F, Landers J: Metastatic carcinoma in the central nervous system and dorsal root ganglia. A prospective autopsy study. J Neurosurg 88:11-20, 1963
4. Ransohoff J: Surgical management of metastatic tumors. Semin Oncol 2:21-27, 1975
5. Veith R, Odom G: Intracranial metastases and their neurosurgical treatment. J Neurosurg 23:375-383, 1965
6. Sampson J, Carter J, Friedman A, et al: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Nerosurg 88:11-20, 1998
7. Amer M, Al-Sarraf M, Vaitkevicius V: Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 149:687-692, 1979
8. Budman D, Camacho E, Wittes R: The current causes of death in patients with malignant melanoma. Eur J Cancer 14:327-330, 1978
9. Kirkwood J, Hunt-Strawderman M, Ernstoff M, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
10. Mitchell MS: Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:1701-1709, 1989
11. Stevens G, Firth I, Coates A: Cerebral metastases from malignant melanoma. Radiother Oncol 23:185-191, 1992
12. Choi KN, Withers HR, Rotman M: Intracranial metastases from melanoma: Clinical features and treatment by accelerated fractionation. Cancer 56:10-15, 1985
13. Rate W, Solin L, Turrisi A: Palliative radiotherapy for metastatic malignant melanoma: Brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 15:859-864, 1988
14. Wronski M, Arbit E: Surgical treatment of brain metastases from melanoma: A retrospective study of 91 patients. J Neurosurg 93:9-18, 2000
15. Mori Y, Kondziolka D, Flickinger J, et al: Stereotactic radiosurgery for cerebral metastatic melanoma: Factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42:581- 589, 1998
16. Somaza S, Kondziolka D, Lundsford L, et al: Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 79:661-666, 1993
17. Seung, S, Hui-Kuo G, McDermott M, et al: Stereotactic radiosurgery for malignant melanoma to the brain. Surg Clin North Am 76:1399-1411, 1996
18. Smalley S, Laws E Jr, O'Fallon J, et al: Resection for solitary brain metastasis. J Neurosurg 77:531-540, 1992
19. Patchell R, Tibbs P, Walsh J, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990
20. Sause W, Crowley J, Morantz R, et al: Solitary brain metastasis: Results of an RTOG/SWOG protocol evaluation surgery + RT versus RT alone. Am J Clin Oncol 13:427-432, 1990
21. Brega K, Robinson W, Winston K, et al: Surgical treatment of brain metastases in malignant melanoma. Cancer 66:2105-2110, 1990
22. Skibber J, Soong S-J, Austin L, et al: Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3:118-123, 1996
23. Nieder C, Schwerdtfeger K, Steudel W-I, et al: Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlenther Onkol 174:275-278, 1998
24. Hagen N, Cirrincione C, Thalėr H, et al: The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 40:158-160, 1990
25. Konefal J, Emami B, Pilepich M: Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 61:243-246, 1988
26. Doss L, Memula M: The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 8:1131-1134, 1985
27. Overgaard J: The role of radiotherapy in recurrent and metastatic malignant melanoma: A clinical radiobiological study. Int J Radiat Oncol Biol Phys 12:867-872, 1986
28. Hall EJ (ed): Radiobiology for the Radiologist. Philadelphia, PA, Lippincott, 1994
29. Strauss A, Dritschilo A, Nathanson L, et al: Radiation therapy of malignant melanomas: An evaluation of clinically used fractionated schemes. Cancer 47:1262-1266, 1981
30. Adam J, Habeshaw T, Kirk J: Response rate of malignant melanoma to large fraction irradiation. Br J Radiol 55:605-607, 1982
31. Overgaard J: Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 6:41-44, 1980
32. Geara F, Ang K: Radiation therapy for malignant melanoma. Surg Clin North Am 76:1383-1399, 1996
33. Overgaard J, von der Maase H, Overgaard M: A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 11:1837-1839, 1985
34. Sause W, Cooper J, Rush S, et al: Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20:429-432, 1991
35. Leksell L: The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102:316-319, 1951
36. Lee H, Posner J: Radiosurgery for metastases from malignant melanoma. Cancer J Sci Am 4:80-83, 1998
37. Alexander E III, Loeffler J: Intracranial metastatic tumor management. Clin Neurosurg 45:32-40, 1999
38. Flickinger J, Lunsford L, Salvador S, et al: Radiosurgery: Its role in brain metastasis management. Neurosurg Clin North Am 7:497-504, 1996
39. Gieger M, Wu J, Ling M, et al: Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Invest 5:72-80, 1997
40. Young R: Radiosurgery for the treetment of brain metastases. Semin Surg Oncol 14:70-78, 1998
41. Schoeggl A, Kitz K, Ertl A, et al: Prognostic factor analysis for multiple brain metastases after gamma knife radiosurgery: Results in 97 patients. J NeurooncoI 42:169-175, 1999
42. Shiau C, Sneed P, Shu H, et al: Radiosurgery for brain metastases: Relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys 37:375-383, 1997
43. Williams J, Enger C, Wharam M, et al: Stereotactic radiosurgery for brain metastases: Comparison of lung carcinoma vs. non-lung tumors. J Neurooncol 37:79-85, 1998
44. Loeffler J, Barker F, Chapman P: Role of radiosurgery in the management of central nervous system metastases. Cancer Chemother Pharmacol 43:11-14, 1999 (suppl)
45. Grob J, Regis J, Laurans R, et al: Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Eur J Cancer 34:1187-1192, 1998
46. Pirzkall AJD, Lohr F, Fuss M, et al: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16:3563-3569, 1998
47. Shaw E, Scott C, Souhami L, et al: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291-298, 2000
48. Seung S, Sneed P, McDermott M, et al: Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Scien Am 4:103-109, 1998
49. Sperduto P, Scott C, Andrews D, et al: Preliminary report of RTOG 9508: A phase III trial comparing whole brain irradiation alone versus whole brain irradiation plus stereotactic radiosurgery for patients with two or three unresected brain metastases. Int J Radiat Oncol Biol Phys 48:113, 2001 (suppl, abstr)
50. Jacquillat C, Khayat D, Banzet P, et al: Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66:873-1878, 1990
51. Kleeberg UR, Engel E, Israels P, et al: Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 5:195-200, 1995
52. Khayat D, Giroux B, Berille J, et al: Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 12:414-420, 1994
53. Falkson CI, Falkson G, Falkson HC: Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 12:251-254, 1994
54. Brocker EB, Bohndorf W Kampgen E, et al: Fotemusine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res 6:399-401, 1996
55. Hammond LA, Eckardt JR, Baker SD, et al: Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17:2604-2613, 1999
56. Patel M, McCully C, Godwin K, et al: Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 14:461, 1995 (abstr 1485)
57. Newlands ES, Blackledge GRP, Slack JA, et al: Phase I trial of temozolomide. Br J Cancer 65:287-291, 1992
58. Dhodapkar M, Rubin J, Reid JM, et al: Phase I trial of temozolomide in patients with advanced cancer. Clin Cancer Res 3:1093-1100, 1997
59. Middleton MR, Gore M, Tilgen W, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced, metastatic melanoma. J Clin Oncol 18:158-166, 2000
60. Brock CS, Newlands ES, Wedge SR, et al: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367, 1998
61. Stupp R., Maillard I, Pica A, et al: Daily temozolomide and concomitant radiotherapy followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme: A well tolerated and promising regimen. Proc Am Soc Clin Oncol 18:154a, 1999 (abstr 592)
62. Newlands ES, Wedge SR, Porteous JK, et al: Temozolomide: Drug scheduling in vivo and in combination with radiation. Proc Am Soc Clin Oncol 16:393a, 1997 (abstr 1403)
63. Margolin K, Atkins MB, Thompson JA, et al: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218, 2002
64. Atkins MB, Gollob JA, Mier JW, et al: Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide (CVT), interleukin 2 (IL-2) and interferon α-2B (IFN) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 20:349a, 2001 (abstr 1391)
65. Sampaio EP, Sarno EN, Galilly R, et al: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699-703, 1991
66. Hwu W-J, Krown SE, Mennell JH, et al: Temozolomide plus thalidomide in patients with advanced melanoma: A phase II trial. Proc Am Soc Clin Oncol 21:344a, 2002 (abstr 1372)